<DOC>
	<DOCNO>NCT02910245</DOCNO>
	<brief_summary>This project double-blind , randomize , placebo-controlled , multicenter trial Netherlands . The aim study investigate therapeutic efficacy optimize 6-mercaptopurine ( 6-MP ) ulcerative colitis patient . Therapeutic drug monitoring ( TDM ) perform order optimize treatment outcomes objective endoscopic endpoint use .</brief_summary>
	<brief_title>Mercaptopurine Therapy Ulcerative Colitis</brief_title>
	<detailed_description>Subjects receive treatment oral prednisone 40 mg/day 2 week , follow fix taper 6 week . Half subject randomize concomitant 6-MP 1-1.5 mg/kg/day half receive concomitant placebo treatment . During entire course trial subject receive maintenance treatment 5-ASA oral dose least 2 gram per day . Subjects subject one colonoscopy baseline one sigmoidoscopy week 52 order ass endoscopic disease activity . Data collect use electronic case report form ( eCRF ) Castor EDC . Quality data validation procedure apply ensure validity accuracy clinical database . Monitoring study do accord GCP guideline follow monitoring plan . The financier study , ZonMw Goed Gebruik Geneesmiddelen , right perform audit see necessary .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<criteria>1 . Confirmed diagnosis UC endoscopy histopathology 2 . Patients 18 80 year age 3 . Active disease , despite oral treatment least 2g/day 5ASA 4 . Treatment oral corticosteroid require 1 . Prior treatment thiopurines 2 . Prior treatment biologics ( e.g . antiTNF agent vedolizumab ) 3 . Current pregnancy ( pregnancy test perform necessary accord treat physician ) 4 . Chronic Obstructive Pulmonary Disease ( COPD ) 5 . Acute coronary heart disease 6 . ( Bacterial ) gastroenteritis treat first 7 . Coagulation disorder 8 . Active malignancy 9 . History colonic dysplasia/cancer 10 . Extensive colonic resection , i.e . subtotal colectomy &lt; 15 cm colon situ 11 . Concomitant therapy drug interfere MP metabolism , like allopurinol , ribavirin antiepileptic . 12 . Known systemic fungal infection parasitic infection treat first 13 . Known duodenal ventricular ulcus 14 . Substance abuse , alcohol ( &gt; 80 gram/day one standard glass contain 10 gram alcohol ) , I.V . drug inhale drug . If subject history substance abuse , consider inclusion protocol , subject must abstain use abused substance least 2 year . Subjects receive methadone within past 2 year also exclude 15 . Positive tuberculosis screen ( screen perform discretion treat physician ) 16 . Active hepatitis B virus hepatitis C virus infection define positive antiHCV , HBsAg and/or antiHBcore screening . 17 . Leucopenia ( Neutrophil count &lt; 1,8x10^9/L ) 18 . Thrombopenia ( Platelets &lt; 90x10^9/L ) 19 . Elevated liver enzyme ( &gt; 2x ULN ) 20 . Abnormal renal function ( eGFR &lt; 30 mL/min ) 21 . Other condition opinion investigator may interfere subject 's ability comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Therapeutic Drug Monitoring</keyword>
	<keyword>Mercaptopurine ( 6-MP )</keyword>
	<keyword>Thiopurine</keyword>
	<keyword>Efficacy</keyword>
</DOC>